Abstract
HORIBA Ltd. has been developing an automated blood glucose analyzer for point-of-care testing (POCT) as part of the Antsense series. The latest model, the Antsense Duo, was launched in late 2013. In this study, we evaluate the basic performance of the Antsense Duo. Its repeatability, linearity, correlation against those of GA-08 (A&T Corp.), and interference effects on coexisting materials such as dissolved oxygen (DO) were evaluated. Ten continuous runs on whole blood samples with various glucose concentrations were performed for the repeatability study. The mean, standard deviation (SD), and coefficient of variation (CV%) were calculated. Samples in the 60–400 mg/dL range showed CV% values between 1.0 and 2.3%, and samples with a glucose concentration lower than 60 mg/dL showed a CV% lower than 3%. The linearity test was carried out between 10–1,000 mg/dL with acceptable results. The correlation between whole blood samples measured with the Antsense Duo and plasma samples measured with GA08 (A&T Corp.) was examined. The result showed a correlation coefficient (r2) of 0.997, which is considered high, and the regression was calculated to be y = 1.04x – 4.32. Samples with low hematocrit values showed 5.0–9.0% higher CV% and samples with high hematocrit values showed 11% lower CV%. No interference effects on DO and other coexisting materials were observed. From the evaluation, the Antsense Duo seemed suitable as a blood glucose analyzer for POCT use.
